These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 31701485)

  • 21. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.
    Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; di Cantogno EV
    Neurodegener Dis Manag; 2023 Oct; 13(5):261-268. PubMed ID: 37535336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
    Cook S; Vermersch P; Comi G; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Hamlett A; Miret M; Weiner J; Viglietta V; Musch B; Greenberg SJ;
    Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
    Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
    Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
    Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Jack D; Vermersch P
    Neurodegener Dis Manag; 2022 Dec; 12(6):295-301. PubMed ID: 36017780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cladribine vs other drugs in MS: Merging randomized trial with real-life data.
    Signori A; Saccà F; Lanzillo R; Maniscalco GT; Signoriello E; Repice AM; Annovazzi P; Baroncini D; Clerico M; Binello E; Cerqua R; Mataluni G; Perini P; Bonavita S; Lavorgna L; Zarbo IR; Laroni A; Pareja-Gutierrez L; La Gioia S; Frigeni B; Barcella V; Frau J; Cocco E; Fenu G; Clerici VT; Sartori A; Rasia S; Cordioli C; Stromillo ML; Di Sapio A; Pontecorvo S; Grasso R; Barone S; Barrilà C; Russo CV; Esposito S; Ippolito D; Landi D; Visconti A; Sormani MP
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32801167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
    Leist TP; Comi G; Cree BA; Coyle PK; Freedman MS; Hartung HP; Vermersch P; Casset-Semanaz F; Scaramozza M;
    Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis.
    Tafazzoli A; Chavan A; Harty G; Moller J; Wong SL
    Adv Ther; 2020 Sep; 37(9):3791-3806. PubMed ID: 32647909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cladribine tablets: in relapsing-remitting multiple sclerosis.
    Muir VJ; Plosker GL
    CNS Drugs; 2011 Mar; 25(3):239-49. PubMed ID: 21323395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cladribine Tablets: A Review in Relapsing MS.
    Deeks ED
    CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
    Sorensen PS; Pontieri L; Joensen H; Heick A; Rasmussen PV; Schäfer J; Ratzer R; Pihl CE; Sellebjerg F; Magyari M
    Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis.
    Hermann R; Litwin JS; Friberg LE; Dangond F; Munafo A
    Br J Clin Pharmacol; 2019 Jul; 85(7):1484-1494. PubMed ID: 30883839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Lambe T; Duarte R; Mahon J; Nevitt S; Greenhalgh J; Boland A; Beale S; Kotas E; McEntee J; Pomeroy I
    Pharmacoeconomics; 2019 Mar; 37(3):345-357. PubMed ID: 30328051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
    Comi G; Hartung HP; Kurukulasuriya NC; Greenberg SJ; Scaramozza M
    Expert Opin Pharmacother; 2013 Jan; 14(1):123-36. PubMed ID: 23256518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis.
    Leist T; Cook S; Comi G; Montalban X; Giovannoni G; Nolting A; Damian D; Syed S; Galazka A
    Mult Scler Relat Disord; 2020 Nov; 46():102572. PubMed ID: 33296971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
    Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Van Der Walt A; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Blanco Morgado Y; Spitaleri D; van Pesch V; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H
    Mult Scler; 2023 Feb; 29(2):221-235. PubMed ID: 36433775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study.
    Brownlee W; Amin A; Ashton L; Herbert A
    Mult Scler Relat Disord; 2023 Nov; 79():104951. PubMed ID: 37639781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
    Poveda JL; Trillo JL; Rubio-Terrés C; Rubio-Rodríguez D; Polanco A; Torres C
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):295-303. PubMed ID: 31220959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.
    Rammohan K; Coyle PK; Sylvester E; Galazka A; Dangond F; Grosso M; Leist TP
    Drugs; 2020 Dec; 80(18):1901-1928. PubMed ID: 33247831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis.
    Terranova N; Hicking C; Dangond F; Munafo A
    Clin Pharmacokinet; 2019 Mar; 58(3):325-333. PubMed ID: 29992396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
    Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL
    Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.